

Care Source NETWORK Notification

Notice Date: February **5**, 2025

Georgia Medicaid Providers To:

From: CareSource

Subject: **Avalon Q3 2024 Quarterly Laboratory Policy Updates**

Effective Date: April 1, 2025

This notification is a revision to the network notification posted on February 1, 2025. Updates are in red font.

Summary

CareSource has partnered with Avalon Healthcare Solutions for laboratory benefits management (LBM), including routine testing management (RTM), a post-service pre-payment clinical claim editing program for routine lab testing.

The RTM program is based on ensuring compliance with the lab policies located on Avalon's website.

This notification is intended to provide you notification of changes to the policies listed below. The policies appear on Avalon website upon their effective dates.

Policies

Policy Name	Plans	Effective Date
F2019 – Flow Cytometry	GEORGIA MEDICAID	04/01/2025
G2002 – Cervical Cancer	GEORGIA MEDICAID	04/01/2025
Screening		
G2007 – Prostate Biopsy	GEORGIA MEDICAID	04/01/2025
Specimen Analysis		
G2035 – Prenatal Screening	GEORGIA MEDICAID	04/01/2025
(Nongenetic)		
G2036 – Hepatitis Testing	GEORGIA MEDICAID	04/01/2025
G2043 – Celiac Disease Testing	GEORGIA MEDICAID	04/01/2025
G2045 – Thyroid Disease Testing	GEORGIA MEDICAID	04/01/2025
G2048 – Biochemical Markers of	GEORGIA MEDICAID	04/01/2025
Alzheimer Disease and Dementia		
G2050 – Cardiovascular Disease	GEORGIA MEDICAID	04/01/2025
Risk Assessment		
G2051 – Bone Turnover Markers	GEORGIA MEDICAID	04/01/2025
Testing		

G2059 – Epithelial Cell Cytology in	GEORGIA MEDICAID	04/01/2025
Breast Cancer Risk Assessment		
G2060 – Fecal Analysis in the	GEORGIA MEDICAID	04/01/2025
Diagnosis of Intestinal Dysbiosis		
and Fecal Microbiota Transplant		
Testing		
G2061 – Fecal Calprotectin	GEORGIA MEDICAID	04/01/2025
Testing in Adults		
G2063 – Testing for Diagnosis of	GEORGIA MEDICAID	04/01/2025
Active or Latent Tuberculosis		
G2100 – In Vitro Chemoresistance	GEORGIA MEDICAID	04/01/2025
and Chemosensitivity Assays		
G2105 - Immunopharmacologic	GEORGIA MEDICAID	04/01/2025
Monitoring of Therapeutic Serum		
Antibodies		
G2107 – Measurement of	GEORGIA MEDICAID	04/01/2025
Thromboxane Metabolites for ASA		
Resistance		
G2110 – Serum Testing for	GEORGIA MEDICAID	04/01/2025
Hepatic Fibrosis in the Evaluation		
and Monitoring of Chronic Liver		
Disease		
G2113 – Oral Cancer Screening	GEORGIA MEDICAID	04/01/2025
and Testing		
G2115 – Metabolite Markers of	GEORGIA MEDICAID	04/01/2025
Thiopurines Testing		0 .70 .72020
G2119 – Diagnostic Testing of	GEORGIA MEDICAID	04/01/2025
Influenza		5/1/2024-12/31/2024
G2121 – Laboratory Testing for the	GEORGIA MEDICAID	04/01/2025
Diagnosis of Inflammatory Bowel		
Disease		
G2123 – Serum Biomarker Testing	GEORGIA MEDICAID	04/01/2025
for Multiple Sclerosis and Related		
Neurologic Diseases		
G2124 – Serum Tumor Markers for	GEORGIA MEDICAID	04/01/2025
Malignancies		
G2149 – Pathogen Panel Testing	GEORGIA MEDICAID	04/01/2025
G2150 – Biomarkers for	GEORGIA MEDICAID	04/01/2025
Myocardial Infarction and Chronic		
Heart Failure		
G2151 – Serum Testing for	GEORGIA MEDICAID	04/01/2025
Evidence of Mild Traumatic Brain		0 1/0 1/2020
Injury		
G2153 – Pancreatic Enzyme	GEORGIA MEDICAID	04/01/2025
Testing for Acute Pancreatitis	221.00.125107.115	3 3 2 3 2 3
G2154 – Folate Testing	GEORGIA MEDICAID	04/01/2025
G2155 – General Inflammation	GEORGIA MEDICAID	04/01/2025
Testing		3 1/3 1/2323
G2156 – Urine Culture Testing for	GEORGIA MEDICAID	04/01/2025
Bacteria	323. (3), (MEDIO) (ID	3 1/0 1/2020
G2157 – Diagnostic Testing of	GEORGIA MEDICAID	04/01/2025
Common Sexually Transmitted	323. (3), (MEDIO) (ID	3 1/0 1/2020
Infections		

G2158 – Testing for Vector-borne Infections	GEORGIA MEDICAID	04/01/2025
G2159 – β - Hemolytic	GEORGIA MEDICAID	04/01/2025
Streptococcus Testing		
G2173 – Gamma-glutamyl	GEORGIA MEDICAID	04/01/2025
Transferase Testing in Adults		
M2041 – Venous and Arterial	GEORGIA MEDICAID	04/01/2025
Thrombosis Risk Testing		
M2068 – Testing for Alpha-1	GEORGIA MEDICAID	04/01/2025
Antitrypsin Deficiency		
M2097 – Identification of	GEORGIA MEDICAID	04/01/2025
Microorganisms Using Nucleic Acid		
Probes		
M2112 – Nerve Fiber Density	GEORGIA MEDICAID	04/01/2025
Testing		

Trial Claim Advice Tool

Providers may use the Trial Claim Advice tool to review claims with laboratory services for adherence and consistency with CareSource laboratory policies. This is a simulation tool and does not guarantee approval or reimbursement of claims. You can access the Trial Claim Advice Tool on the CareSource Provider Portal.

GA-MED-P-3458651a DCH Approved: 12/13/2024